Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from COSCIENS Biopharma ( (TSE:CSCI) ).
On April 20, 2026, COSCIENS Biopharma filed a preliminary management proxy circular with the U.S. Securities and Exchange Commission ahead of its virtual annual general and special meeting expected in June 2026. Shareholders will be asked to receive the 2025 financial statements, re-elect the current six-member board, and appoint Deloitte LLP as external auditor, with voting conducted online due to the fully virtual meeting format.
The most consequential item is a proposed share capital amendment combining a 1-for-150 share consolidation with an immediate 50-for-1 share split. Holders with positions below the consolidation threshold would be cashed out at U.S.$1.60 per pre-consolidation share, a structure designed primarily to reduce the number of U.S. holders of record under securities rules, which could streamline the company’s reporting obligations and alter its shareholder base composition.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc. is a Canada-based biopharmaceutical company listed on the TSX and OTCQB under the tickers CSCI and CSCIF. The firm operates under the Canada Business Corporations Act and focuses on developing and commercializing pharmaceutical products, with its shareholder base split between Canadian and U.S. investors and governed by North American securities regulations.
YTD Price Performance: -7.39%
Average Trading Volume: 4,421
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$8.37M
See more insights into CSCI stock on TipRanks’ Stock Analysis page.